A STUDY OF THE INTERACTION OF OMEPRAZOLE AND WARFARIN IN ANTICOAGULATED PATIENTS

被引:67
作者
UNGE, P
SVEDBERG, LE
NORDGREN, A
BLOM, H
ANDERSSON, T
LAGERSTROM, PO
IDSTROM, JP
机构
[1] ASTRA HASSLE AB,S-43183 MOLNDAL,SWEDEN
[2] BOLLNAS HOSP,DEPT MED,BOLLNAS,SWEDEN
[3] SANDVIKEN HOSP,DEPT MED,SANDVIKEN,SWEDEN
关键词
OMEPRAZOLE; WARFARIN; INTERACTION; PATIENTS; ANTICOAGULATION;
D O I
10.1111/j.1365-2125.1992.tb05656.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 Thirty-five patients on continuous therapy with warfarin were given omeprazole 20 mg once daily and placebo each for 3 weeks according to a two-centre randomised double-blind cross-over design. 2 Blood samples were obtained once weekly during the run-in and follow-up periods as well as during the first 2 weeks of each treatment period, and twice during the last week of each treatment period. Plasma concentrations of R- and S-warfarin were measured by h.p.l.c. and the anticoagulant effect was assessed using the Trombotest(R). 3 Twenty-eight patients were evaluated. The mean plasma concentration of R-warfarin was increased by 9.5% during omeprazole treatment compared with placebo, while that of S-warfarin, the more active isomer, was unaffected. The coagulation time was not significantly changed (106 s during omeprazole and 98 s during placebo). Corresponding TT-values (Trombotest(R)) were 8.8 and 9.9 (NS).
引用
收藏
页码:509 / 512
页数:4
相关论文
共 12 条
  • [1] EFFECT OF OMEPRAZOLE TREATMENT ON DIAZEPAM PLASMA-LEVELS IN SLOW VERSUS NORMAL RAPID METABOLIZERS OF OMEPRAZOLE
    ANDERSSON, T
    CEDERBERG, C
    EDVARDSSON, G
    HEGGELUND, A
    LUNDBORG, P
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 47 (01) : 79 - 85
  • [2] OMEPRAZOLE DRUG-INTERACTION STUDIES
    ANDERSSON, T
    [J]. CLINICAL PHARMACOKINETICS, 1991, 21 (03) : 195 - 212
  • [3] SLOW OMEPRAZOLE METABOLIZERS ARE ALSO POOR S-MEPHENYTOIN HYDROXYLATORS
    ANDERSSON, T
    REGARDH, CG
    DAHLPUUSTINEN, ML
    BERTILSSON, L
    [J]. THERAPEUTIC DRUG MONITORING, 1990, 12 (04) : 415 - 416
  • [4] IMPORTANCE OF GENETIC-FACTORS IN THE REGULATION OF DIAZEPAM METABOLISM - RELATIONSHIP TO S-MEPHENYTOIN, BUT NOT DEBRISOQUIN, HYDROXYLATION PHENOTYPE
    BERTILSSON, L
    HENTHORN, TK
    SANZ, E
    TYBRING, G
    SAWE, J
    VILLEN, T
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (04) : 348 - 355
  • [5] SUBSTITUTED BENZIMIDAZOLES INHIBIT GASTRIC-ACID SECRETION BY BLOCKING (H++K+)ATPASE
    FELLENIUS, E
    BERGLINDH, T
    SACHS, G
    OLBE, L
    ELANDER, B
    SJOSTRAND, SE
    WALLMARK, B
    [J]. NATURE, 1981, 290 (5802) : 159 - 161
  • [6] WARFARIN AS A PROBE OF CYTOCHROMES-P-450 FUNCTION
    KAMINSKY, LS
    [J]. DRUG METABOLISM REVIEWS, 1989, 20 (2-4) : 479 - 487
  • [7] POCOCK SJ, 1983, CLIN TRIALS PRACTICA, P116
  • [8] RELLING MV, 1990, J PHARMACOL EXP THER, V252, P442
  • [9] STEREOSELECTIVE INTERACTION OF OMEPRAZOLE WITH WARFARIN IN HEALTHY-MEN
    SUTFIN, T
    BALMER, K
    BOSTROM, H
    ERIKSSON, S
    HOGLUND, P
    PAULSEN, O
    [J]. THERAPEUTIC DRUG MONITORING, 1989, 11 (02) : 176 - 184
  • [10] TOLBUTAMIDE AND PHENYTOIN HYDROXYLATIONS BY CDNA-EXPRESSED HUMAN LIVER CYTOCHROME-P4502C9
    VERONESE, ME
    MACKENZIE, PI
    DOECKE, CJ
    MCMANUS, ME
    MINERS, JO
    BIRKETT, DJ
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 175 (03) : 1112 - 1118